These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3415420)

  • 21. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study.
    Tapp AJ; Cardozo LD; Versi E; Cooper D
    Br J Obstet Gynaecol; 1990 Jun; 97(6):521-6. PubMed ID: 2198921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial.
    Enzelsberger H; Helmer H; Kurz C
    Br J Obstet Gynaecol; 1995 Nov; 102(11):929-30. PubMed ID: 8534633
    [No Abstract]   [Full Text] [Related]  

  • 23. S-oxybutynin.
    Drugs R D; 2002; 3(2):84-5. PubMed ID: 12001823
    [No Abstract]   [Full Text] [Related]  

  • 24. The use of salivary stimulant pastilles to improve compliance in women taking oxybutinin hydrochloride for detrusor instability.
    Arango O
    Br J Urol; 1998 Apr; 81(4):652. PubMed ID: 9598656
    [No Abstract]   [Full Text] [Related]  

  • 25. Case 7: the addled nonagenarian.
    Shader RI; Oesterheld JR
    J Clin Psychopharmacol; 1995 Oct; 15(5):378. PubMed ID: 8830074
    [No Abstract]   [Full Text] [Related]  

  • 26. [Anticholinergic treatment in the therapy of primary enuresis. Effectiveness of oxybutynin chloride in a controlled clinical study of 58 patients].
    Marconi AM; Felici E; Roggia A; Torelli F
    Pediatr Med Chir; 1985; 7(4):573-6. PubMed ID: 3915547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxybutynin: is it safe?
    Baigrie RJ; Kelleher JP; Fawcett DP; Pengelly AW
    Br J Urol; 1988 Oct; 62(4):319-22. PubMed ID: 3191355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
    Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
    Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transdermal oxybutynin. A viewpoint by Michael Chancellor.
    Chancellor M
    Drugs Aging; 2003; 20(11):865-6. PubMed ID: 12964893
    [No Abstract]   [Full Text] [Related]  

  • 30. [Drug therapy of enuresis].
    von Gontard A; Lehmkuhl G
    Z Kinder Jugendpsychiatr Psychother; 1996 Mar; 24(1):18-33. PubMed ID: 9459680
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of hyperhidrosis with oxybutynin.
    Schollhammer M; Misery L
    Arch Dermatol; 2007 Apr; 143(4):544-5. PubMed ID: 17438194
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Abrams P; Cardozo L; Chapple C; Serdarevic D; Hargreaves K; Khullar V;
    Int J Urol; 2006 Jun; 13(6):692-8. PubMed ID: 16834644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence of detrusor hyperreflexia in a continent, institutionalized elderly patient with Parkinson's disease.
    Starer P; Libow LS
    N Y State J Med; 1991 Apr; 91(4):166-7. PubMed ID: 2047037
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of oxybutynin treatment on cognition in children with diurnal incontinence.
    Sommer BR; O'Hara R; Askari N; Kraemer HC; Kennedy WA
    J Urol; 2005 Jun; 173(6):2125-7. PubMed ID: 15879864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
    Gupta SK; Sathyan G
    J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal oxybutynin. A viewpoint by Adrian Wagg.
    Wagg A
    Drugs Aging; 2003; 20(11):865-6. PubMed ID: 12964894
    [No Abstract]   [Full Text] [Related]  

  • 37. Transdermal oxybutynin (oxytrol) for urinary incontinence.
    Dull P
    Am Fam Physician; 2004 Dec; 70(12):2351-2. PubMed ID: 15617300
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients.
    Ouslander JG; Blaustein J; Connor A; Orzeck S; Yong CL
    J Urol; 1988 Jul; 140(1):47-50. PubMed ID: 3379694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Use of oxybutynin hydrochloride in the treatment of primary dysmenorrhea].
    Piato S; Delascio D
    Matern Infanc (Sao Paulo); 1968; 27(2):95-101. PubMed ID: 5746834
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.